AG
ADPT icon

Advisor Group’s Adaptive Biotechnologies ADPT Stock Holding History

Advisor Group’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$6K Sell
183
-156
-46% -$4.48K ﹤0.01% 4564
2019
Q3 		$10K Buy
+339
New +$13.8K ﹤0.01% 4326

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
SIG
Senator Investment Group New York $2.74B AUM 55.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
TM
Tiger Management New York $22.8M AUM 0.71% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Advisor Group's ADPT Position: Q4 2019 in Review

Advisor Group reduced its Adaptive Biotechnologies (ADPT) stake by 46% in Q4 2019, selling an estimated $4.48K and leaving 183 shares worth $6K. The position accounts for ﹤0.01% of the portfolio, ranked #4564.

Advisor Group first reported a position in ADPT in Q3 2019 and has held it in 2 quarters since. The position peaked at $10K in Q3 2019. 133 funds tracked by Wall St. Rank hold ADPT as of Q4 2019.

  • Advisor Group held 183 shares of Adaptive Biotechnologies worth $6K as of Q4 2019.
  • Advisor Group sold 156 Adaptive Biotechnologies shares in Q4 2019, an estimated $4.48K.
  • Adaptive Biotechnologies made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #4564 holding.
  • Advisor Group first reported a position in Adaptive Biotechnologies in Q3 2019 and has held it in 2 quarters since.
  • Advisor Group's Adaptive Biotechnologies position peaked at $10K in Q3 2019.
  • 133 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.